Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Inclusion Criteria

• •1. Age \> 1 month and \< 26 years
• •2. Life expectancy \> 10 weeks
• •3. Subjects deemed eligible for allogeneic stem cell transplantation.
• •4. Subjects with life-threatening hematological malignancies (high-risk ALL in 1st CR, ALL in 2nd or subsequent CR, AML in 1st CR, AML in 2nd or subsequent CR, myelodysplastic syndromes, non-Hodgkin lymphomas in 2nd or subsequent CR, other hematologic malignancies eligible for stem cell transplantation per institutional standard);
• •5. Non-malignant disorders amenable to cure by an allograft:
• •1. primary immune deficiencies,
• •2. severe aplastic anemia not responding to immune suppressive therapy,
• •3. osteopetrosis,
• •4. hemoglobinopathies, (thalassemias, and sickle cell anemia, and Diamond-Blackfan anemia among others)
• •6. Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative or 10/10 unrelated donor evaluated using high resolution molecular typing) or presence of rapidly progressive disease not permitting time to identify an unrelated donor
• •7. A minimum genotypic identical match of 5/ 10 is required.
• •8. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA- DRB1 and HLA-DQB1.
• •9. Lansky/Karnofsky score \> 50
• •10. Signed written informed consent